Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Viracept

Known as: Agouron Brand of Nelfinavir Mesylate, Roche Brand of Nelfinavir Mesylate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
Nelfinavir (Viracept) was originally designed as a specific HIV protease inhibitor and, since its introduction in 1997, has… Expand
Is this relevant?
2009
2009
Viracept (nelfinavir) is an HIV protease inhibitor supplied by Roche outside the US, Canada and Japan. Viracept was first… Expand
  • table 1
Is this relevant?
2009
2009
This perspective first considers the potential impact of the Viracept-EMS case in the framework of the current understanding of… Expand
Is this relevant?
2009
2009
In May 2007, the F. Hoffmann-La Roche Company became aware of a contamination of Viracept (nelfinavir) tablets by the mutagenic… Expand
Is this relevant?
2002
2002
Summary Forty (40) HIV positive patients with CD4 cell counts between 100 - 500 cellh/mm3 were recruited from 8 different centres… Expand
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Nelfinavir mesylate (Viracept, formally AG1343) is a potent and orally bioavailable human immunodeficiency virus (HIV) type 1… Expand
Is this relevant?
2000
2000
Abstract The checkpoint kinase Chk1 is an important mediator of cell cycle arrest following DNA damage. The 1.7 A resolution… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Using a combination of iterative structure-based design and an analysis of oral pharmacokinetics and antiviral activity, AG1343… Expand
Is this relevant?
1997
1997
The Food and Drug Administration (FDA) approved nelfinavir (Viracept) for both adult and pediatric use for treatment of HIV… Expand
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Background: Non-invasive surrogate measures which are valid and responsive to change are needed to study cardiovascular risks in… Expand
  • figure 1
  • figure 2
  • table 3
  • table 4
  • table 1
Is this relevant?